Media Summary: Shares of companies involved in psychedelic-tied therapies surged Monday after President Donald Trump signed an executive ... In this week's episode of the Xtalks Life Science Podcast, host Ayesha Rashid, Senior Life Science Journalist at Xtalks, spoke with ... The Trump administration is pushing to fast-track psychedelic drug approvals as his economic approval ratings hit record lows, ...

Compass Pathways 6 Month Data - Detailed Analysis & Overview

Shares of companies involved in psychedelic-tied therapies surged Monday after President Donald Trump signed an executive ... In this week's episode of the Xtalks Life Science Podcast, host Ayesha Rashid, Senior Life Science Journalist at Xtalks, spoke with ... The Trump administration is pushing to fast-track psychedelic drug approvals as his economic approval ratings hit record lows, ... The FDA could approve a psychedelic drug for the first time ever. Welcome back to Griffonomics, where we conduct financial investigations to define the risk before we look at the reward. Today ...

Photo Gallery

Compass Pathways' 6-Month Data | What The Trial Actually Showed
Compass Pathways Eyes FDA Approval for Psilocybin Depression Drug
Psychedelic Therapy's $100B Moment: Why Compass Pathways' COMP 360 Changes Investing
Compass Pathways CEO on Trump's Order to Expand Psychedelics Research
Psilocybin Treatments for Treatment-Resistant Depression with Compass Pathways’ Dr. Steve Levine
Why Trump Is Pushing Psychedelics To Treat Mental Illness
Compass Pathways Q1 2026: Breakthrough in Treatment-Resistant Depression
Compass Pathways uses psychoactive treatment for depression: CEO
What does COMPASS Pathways' recent data on psilocybin mean for psychedelic therapies?
Analyzing the Compass Pathways Phase 3 Psilocybin trial ($CMPS)
Magic mushrooms are about to be FDA approved?
Compass Pathways (CMPS) Stock: 🍄 FDA Acceleration vs. 2026 Durability Showdown
View Detailed Profile
Compass Pathways' 6-Month Data | What The Trial Actually Showed

Compass Pathways' 6-Month Data | What The Trial Actually Showed

Compass Pathways

Compass Pathways Eyes FDA Approval for Psilocybin Depression Drug

Compass Pathways Eyes FDA Approval for Psilocybin Depression Drug

Encouraging trial

Psychedelic Therapy's $100B Moment: Why Compass Pathways' COMP 360 Changes Investing

Psychedelic Therapy's $100B Moment: Why Compass Pathways' COMP 360 Changes Investing

Compass Pathways

Compass Pathways CEO on Trump's Order to Expand Psychedelics Research

Compass Pathways CEO on Trump's Order to Expand Psychedelics Research

Shares of companies involved in psychedelic-tied therapies surged Monday after President Donald Trump signed an executive ...

Psilocybin Treatments for Treatment-Resistant Depression with Compass Pathways’ Dr. Steve Levine

Psilocybin Treatments for Treatment-Resistant Depression with Compass Pathways’ Dr. Steve Levine

In this week's episode of the Xtalks Life Science Podcast, host Ayesha Rashid, Senior Life Science Journalist at Xtalks, spoke with ...

Why Trump Is Pushing Psychedelics To Treat Mental Illness

Why Trump Is Pushing Psychedelics To Treat Mental Illness

The Trump administration is pushing to fast-track psychedelic drug approvals as his economic approval ratings hit record lows, ...

Compass Pathways Q1 2026: Breakthrough in Treatment-Resistant Depression

Compass Pathways Q1 2026: Breakthrough in Treatment-Resistant Depression

Compass Pathways

Compass Pathways uses psychoactive treatment for depression: CEO

Compass Pathways uses psychoactive treatment for depression: CEO

Biotech company

What does COMPASS Pathways' recent data on psilocybin mean for psychedelic therapies?

What does COMPASS Pathways' recent data on psilocybin mean for psychedelic therapies?

In early November of 2021,

Analyzing the Compass Pathways Phase 3 Psilocybin trial ($CMPS)

Analyzing the Compass Pathways Phase 3 Psilocybin trial ($CMPS)

Brom Rector and Sam Tabone analyze

Magic mushrooms are about to be FDA approved?

Magic mushrooms are about to be FDA approved?

The FDA could approve a psychedelic drug for the first time ever.

Compass Pathways (CMPS) Stock: 🍄 FDA Acceleration vs. 2026 Durability Showdown

Compass Pathways (CMPS) Stock: 🍄 FDA Acceleration vs. 2026 Durability Showdown

Welcome back to Griffonomics, where we conduct financial investigations to define the risk before we look at the reward. Today ...

$CMPS Dips on Positive Phase 3 Trial Data for its COMP360 Therapy

$CMPS Dips on Positive Phase 3 Trial Data for its COMP360 Therapy

CMPS -